etodolac has been researched along with Kidney Failure, Chronic in 3 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The mean half-life (t1/2) was 6 to 7 hours." | 2.38 | Profile of etodolac: pharmacokinetic evaluation in special populations. ( Brater, DC; Lasseter, KC, 1989) |
| "Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function." | 1.27 | Effect of etodolac in patients with moderate renal impairment compared with normal subjects. ( Anderson, SA; Brater, DC; Brown-Cartwright, D; Chen, A; Jacob, GB; Toto, RD, 1985) |
| " However, the baseline control collections after chronic dosing did not differ from the no-drug control periods." | 1.27 | Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. ( Anderson, SA; Brater, DC; Brown-Cartwright, D; Toto, RD, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brater, DC | 3 |
| Lasseter, KC | 1 |
| Anderson, SA | 2 |
| Brown-Cartwright, D | 2 |
| Toto, RD | 2 |
| Chen, A | 1 |
| Jacob, GB | 1 |
1 review available for etodolac and Kidney Failure, Chronic
| Article | Year |
|---|---|
Profile of etodolac: pharmacokinetic evaluation in special populations.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Half-Life; Hum | 1989 |
2 other studies available for etodolac and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of etodolac in patients with moderate renal impairment compared with normal subjects.
Topics: Acetates; Adolescent; Adult; Aged; Chlorides; Creatinine; Drug Evaluation; Etodolac; Female; Humans; | 1985 |
Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dinoprostone; Etodolac; Humans; Indom | 1986 |